Evidence map›Paper›PMID 31324444›Full record

ArticleThe Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation2019

Early outcomes for low-risk pediatric heart transplant recipients and steroid avoidance: A multicenter cohort study (Clinical Trials in Organ Transplantation in Children - CTOTC-04).

Jacqueline M Lamour, Kristen L Mason, Daphne T Hsu, Brian Feingold, Elizabeth D Blume, Charles E Canter, Anne I Dipchand, Robert E Shaddy, William T Mahle, Warren A Zuckerman and 9 more

Open access · greenAbstract readMulticenter Study
In one paragraph

Article in The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.7field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Heart Transplantation in Children With Down Syndrome.Journal of the American Heart Association · 2022
    Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 12 institutions in 2 countries.

Jacqueline M LamourDivision of Pediatric Cardiology, Children's Hospital at Montefiore, Bronx, New York, New York. Electronic address: jlamour@montefiore.org.
Kristen L MasonRho Federal Systems Division, Chapel Hill, North Carolina.
Daphne T HsuDivision of Pediatric Cardiology, Children's Hospital at Montefiore, Bronx, New York, New York.
Brian FeingoldDepartments of Pediatrics and Clinical and Translational Science, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Elizabeth D BlumeDepartment of Pediatric Cardiology, Boston Children's Hospital, Boston, Massachusetts.
Charles E CanterDivision of Pediatric Cardiology, Washington University School of Medicine, St. Louis, Missouri.
Anne I DipchandDepartment of Paediatrics, Labatt Family Heart Center, Hospital for Sick Children, Toronto, Ontario, Canada.
Robert E ShaddyDivision of Pediatric Cardiology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
William T MahleDivision of Pediatric Cardiology, Children's Healthcare of Atlanta, Atlanta, Georgia.
Warren A ZuckermanDivision of Pediatric Cardiology, Columbia University Medical Center, New York, New York.
Carol BentlejewskiDivision of Pediatric Cardiology, Columbia University Medical Center, New York, New York.
Brian D ArmstrongRho Federal Systems Division, Chapel Hill, North Carolina.
Yvonne MorrisonRho Federal Systems Division, Chapel Hill, North Carolina.
Helena DiopRho Federal Systems Division, Chapel Hill, North Carolina.
David N IkléRho Federal Systems Division, Chapel Hill, North Carolina.
Jonah OdimTransplantation Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
Adriana ZeeviDepartment of Pathology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
Steven A WebberDepartment of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tennessee.
CTOTC-04 investigators
Rho (United States) · USChildren's Hospital at Montefiore · USColumbia University Irving Medical Center · USBoston Children's Hospital · USChildren's Healthcare of Atlanta · USChildren's Hospital of Philadelphia · USHospital for Sick Children · CANational Institute of Allergy and Infectious Diseases · USUniversity of Pittsburgh · USUniversity of Pittsburgh Medical Center · USVanderbilt University · USWashington University in St. Louis · US

Funding

Transplantation GroupUM2AI117870 · NIAID · RHO FEDERAL SYSTEMS DIVISION, INC. · PI DAVID, GLORIA · 2015 to 2023
$208.1M
Alloantibodies in Cardiac Transplantation - Intervention, Outcomes and MechanismsU01AI077867 · NIAID · VANDERBILT UNIVERSITY · PI WEBBER, STEVEN A. · 2008 to 2012
$5.8M
NIAID NIH HHS U01 AI077867NIAID NIH HHS UM2 AI117870
6 · The paper itself

Abstract

backgroundImmunosuppression strategies have changed over time in pediatric heart transplantation. Thus, comorbidity profiles may have evolved. Clinical Trials in Organ Transplantation in Children-04 is a multicenter, prospective, cohort study assessing the impact of pre-transplant sensitization on outcomes after pediatric heart transplantation. This sub-study reports 1-year outcomes among recipients without pre-transplant donor-specific antibodies (DSAs).

methodsWe recruited consecutive candidates (<21 years) at 8 centers. Sensitization status was determined by a core laboratory. Immunosuppression was standardized as follows: Thymoglobulin induction with tacrolimus and/or mycophenolate mofetil maintenance. Steroids were not used beyond 1 week. Rejection surveillance was by serial biopsy.

resultsThere were 240 transplants. Subjects for this sub-study (n = 186) were non-sensitized (n = 108) or had no DSAs (n = 78). Median age was 6 years, 48.4% were male, and 38.2% had congenital heart disease. Patient survival was 94.5% (95% confidence interval, 90.1-97.0%). Freedom from any type of rejection was 67.5%. Risk factors for rejection were older age at transplant and presence of non-DSAs pre-transplant. Freedom from infection requiring hospitalization/intravenous anti-microbials was 75.4%. Freedom from rehospitalization was 40.3%. New-onset diabetes mellitus and post-transplant lymphoproliferative disorder (PTLD) occurred in 1.6% and 1.1% of subjects, respectively. There was no decline in renal function over the first year. Corticosteroids were used in 14.5% at 1 year.

conclusionsPediatric heart transplantation recipients without DSAs at transplant and managed with a steroid avoidance regimen have excellent short-term survival and a low risk of first-year diabetes mellitus and PTLD. Rehospitalization remains common. These contemporary observations allow for improved caregiver and/or patient counseling and provide the necessary outcomes data to help design future randomized controlled trials.

Indexed as

Heart TransplantationAdolescentAntilymphocyte SerumChildChild, PreschoolCohort StudiesFemaleGlucocorticoidsHumansImmunosuppressive AgentsInfantMaleMycophenolic AcidRisk AssessmentTacrolimusTime FactorsAntilymphocyte SerumGlucocorticoidsImmunosuppressive AgentsMycophenolic AcidTacrolimusthymoglobulinimmunosuppressionoutcomespediatric heart transplantrejectionsteroid avoidance

Identifiers

PMID31324444
PMCPMC8359669
OpenAlexW2951822078

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.